UNC registers Phase 4 trial testing Phathom's vonoprazan in Barrett's Esophagus
A University of North Carolina-sponsored study comparing vonoprazan to standard PPI therapy in Barrett's Esophagus patients was registered, with Phathom Pharmaceuticals listed as a collaborator.
A single new trial record involving Phathom Pharmaceuticals was posted this week.
- The "Efficacy of Potassium-Competitive Acid Blockers in Barrett's Esophagus (PCAB BE Study)" is a Phase 4 study of vonoprazan in patients with nondysplastic Barrett's esophagus, sponsored by the University of North Carolina, Chapel Hill, with Phathom Pharmaceuticals, Inc. listed as a collaborator.1 The study is not yet recruiting, with an estimated start date of 2026-08-31.1 It plans to enroll 12 participants in a single-group, open-label design.1 Participants will switch from their usual PPI to vonoprazan 20 mg once daily for 7-28 days1 after an initial pH monitoring test, with the primary outcome measuring the difference in percent time with pH under 4 during 24-hour pH monitoring on PPI versus PCAB therapy.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.